Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price lifted by stock analysts at Wedbush from $59.00 to $72.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would suggest a potential upside of 17.00% from the company’s current price.

A number of other equities analysts also recently commented on the stock. Citigroup boosted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $62.71.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $61.54 on Monday. The stock’s 50-day moving average is $52.17 and its two-hundred day moving average is $46.99. Kiniksa Pharmaceuticals International has a 1-year low of $26.27 and a 1-year high of $61.12. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 65.76 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Equities research analysts anticipate that Kiniksa Pharmaceuticals International will post 1.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 6,625 shares of the stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the transaction, the chief accounting officer owned 27,418 shares in the company, valued at approximately $1,280,146.42. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at $628,554.60. This trade represents a 51.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently bought and sold shares of the stock. Mark Sheptoff Financial Planning LLC boosted its stake in Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after buying an additional 250 shares in the last quarter. Mariner LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after purchasing an additional 266 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after purchasing an additional 293 shares during the last quarter. Virtus Investment Advisers LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 2.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock worth $678,000 after purchasing an additional 406 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its stake in Kiniksa Pharmaceuticals International by 7.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after purchasing an additional 508 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.